ER Mutation Screening

CE / CME

Estrogen Receptor Mutations in HR+ Breast Cancer: Next-Generation Practice Recommendations on Mutation Screening to Guide Therapeutic Decisions

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.25 Medical Knowledge MOC points

Released: December 31, 2024

Expiration: December 30, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

In which of the following settings would an ESR1 mutation most likely be found and could be used to inform next best therapy?

2.

How would you rate your confidence in planning individualized treatment with oral SERDs for HR+/HER2- MBC progressing after ET based on individual patient and disease characteristics?

3.

Which of the following patients with resected ER+/HER2- EBC would be eligible to enroll in the phase III EMBER-4 study of adjuvant imlunestrant?